Price movement over the last 24 hours
Abeona Therapeutics Inc vs Indonesia Energy Corporation Limited — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Indonesia Energy Corporation Limited trades at $2.8 (market cap $44.31M). The key difference: Abeona Therapeutics Inc is far larger — about 8.4× Indonesia Energy Corporation Limited's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| ABEO | INDO | |
|---|---|---|
Market Cap | $373.32M | $44.31M |
Sector | Health | Energy |
52-Week High | $7.23 | $6.74 |
52-Week Low | $4.17 | $2.49 |
Enterprise Value | $228.22M | $39.69M |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
INDO trades at $2.79 with no recent price movement. The stock shows mixed technical signals with a bullish overall rating but bearish moving averages. Fundamentally, the company reported negative profitability metrics with a -253.4% net income margin on $2M revenue in 2025, though recent news highlights operational progress with new well drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of drilling operations to improve financial performance. Key opportunities include potential revenue growth from new wells, while risks center on continued negative cash flow and profitability challenges. The stock presents speculative potential for investors betting on operational turnaround.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →